KR20240056728A - 치료제를 국소적으로 전달하기 위한 약물 전달 시스템 및 이의 용도 - Google Patents

치료제를 국소적으로 전달하기 위한 약물 전달 시스템 및 이의 용도 Download PDF

Info

Publication number
KR20240056728A
KR20240056728A KR1020247009326A KR20247009326A KR20240056728A KR 20240056728 A KR20240056728 A KR 20240056728A KR 1020247009326 A KR1020247009326 A KR 1020247009326A KR 20247009326 A KR20247009326 A KR 20247009326A KR 20240056728 A KR20240056728 A KR 20240056728A
Authority
KR
South Korea
Prior art keywords
drug delivery
delivery system
group
mmol
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247009326A
Other languages
English (en)
Korean (ko)
Inventor
구올롱 우
웨이지앙 쟝
리츈 펭
하오 쟝
다펭 리
Original Assignee
코발 바이오파마 (상하이) 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코발 바이오파마 (상하이) 컴퍼니 리미티드 filed Critical 코발 바이오파마 (상하이) 컴퍼니 리미티드
Publication of KR20240056728A publication Critical patent/KR20240056728A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247009326A 2021-09-16 2022-09-14 치료제를 국소적으로 전달하기 위한 약물 전달 시스템 및 이의 용도 Pending KR20240056728A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/118666 2021-09-16
CN2021118666 2021-09-16
PCT/CN2022/118658 WO2023040879A1 (en) 2021-09-16 2022-09-14 Drug delivery system for locally delivering therapeutic agents and uses thereof

Publications (1)

Publication Number Publication Date
KR20240056728A true KR20240056728A (ko) 2024-04-30

Family

ID=85602430

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247009326A Pending KR20240056728A (ko) 2021-09-16 2022-09-14 치료제를 국소적으로 전달하기 위한 약물 전달 시스템 및 이의 용도

Country Status (9)

Country Link
US (1) US20240398963A1 (cg-RX-API-DMAC7.html)
EP (1) EP4402152A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024533034A (cg-RX-API-DMAC7.html)
KR (1) KR20240056728A (cg-RX-API-DMAC7.html)
CN (1) CN118019750A (cg-RX-API-DMAC7.html)
AU (1) AU2022348759A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227319A1 (cg-RX-API-DMAC7.html)
IL (1) IL311382A (cg-RX-API-DMAC7.html)
WO (1) WO2023040879A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026002095A1 (en) * 2024-06-26 2026-01-02 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally controlled release of therapeutic agents and uses thereof
CN119735627B (zh) * 2024-12-25 2025-10-21 西北农林科技大学 甾体并3,4二氢吡咯吡嗪酮衍生物及其合成方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009096749A (ja) * 2007-10-16 2009-05-07 Konica Minolta Holdings Inc コレステロール誘導体、リポソーム及びx線用造影剤
SG11201609490QA (en) * 2014-05-15 2016-12-29 Agency Science Tech & Res Polymer-flavonoid conjugate and uses thereof
US10350236B2 (en) * 2015-01-09 2019-07-16 Seikagaku Corporation Chondroitin sulfate derivative and agent for treating bladder diseases
SG11202109152UA (en) * 2019-06-03 2021-12-30 Aihol Corp Hyaluronan conjugates and uses thereof
US11458204B2 (en) * 2020-06-02 2022-10-04 Aihol Corporation Method for improving substitution rate and/or substitution efficiency of hyaluronan-drug conjugates
CN117838875B (zh) * 2020-07-15 2025-01-24 上海椿安生物医药科技有限公司 用于局部递送治疗剂的药物递送系统以及其用途

Also Published As

Publication number Publication date
AU2022348759A1 (en) 2024-01-25
CN118019750A (zh) 2024-05-10
CA3227319A1 (en) 2023-03-23
IL311382A (en) 2024-05-01
US20240398963A1 (en) 2024-12-05
EP4402152A1 (en) 2024-07-24
JP2024533034A (ja) 2024-09-12
WO2023040879A1 (en) 2023-03-23
EP4402152A4 (en) 2026-05-20

Similar Documents

Publication Publication Date Title
KR102908135B1 (ko) 이온화 가능한 지질 화합물
CA3167272A1 (en) Cell surface receptor binding compounds and conjugates
AU2025256194A1 (en) Lymphatic system-directing lipid prodrugs
CN115785124A (zh) Kras g12d抑制剂及其用途
DE69623745T2 (de) Derivate von DC 107
CN115867319B (zh) 用于局部递送治疗剂的药物递送系统以及其用途
CA3042428A1 (en) Steroids and protein-conjugates thereof
TWI641616B (zh) 阿比特龍衍生物及其製備方法和醫藥用途
CN121443581A (zh) 用于肌肉特异性递送的可电离脂质
CA3226268A1 (en) M6pr cell surface receptor binding compounds and conjugates
WO2014027777A2 (ko) 신규한 우르솔릭산 유도체 및 이의 제조 방법
CN103702670A (zh) 苷前体药物类似物的合成和应用
US20240398963A1 (en) Drug delivery system for locally delivering therapeutic agents and uses thereof
EP2863925A1 (de) Sialinsäurederivate
AU2021421161B2 (en) Ligand compounds, conjugates, and applications thereof
WO2023103929A1 (zh) 氟维司群衍生物及其制备方法和医药用途
HK40110475A (en) Drug delivery system for locally delivering therapeutic agents and uses thereof
RU2847196C1 (ru) Система доставки лекарственных средств для локальной доставки терапевтических агентов и ее применения
RU2847196C9 (ru) Система доставки лекарственных средств для локальной доставки терапевтических агентов и ее применения
RU2849554C2 (ru) Конъюгат производного ε-поли-l-лизина с лекарственным средством, промежуточные соединения и их применение
RU2819894C1 (ru) Лигандные соединения, конъюгаты и их применение
HK40107352B (en) Drug delivery system for locally delivering therapeutic agents and uses thereof
WO2026002095A1 (en) Drug delivery system for locally controlled release of therapeutic agents and uses thereof
CA3295983A1 (en) Ionizable lipid for muscle-specific delivery
AU2024202698A1 (en) Three cluster galactose type compound, conjugate, making method and use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240320

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250502

Comment text: Request for Examination of Application